I am assuming this Report will be released to the market.... AND... more importantly, to the USA market.
I would hope so.
The valuation of 69 cents is a strange one and I guess it is difficult to find appropriate criteria upon which to base it.
I found it impossible to follow.... (discounted cash flows up until 2032) but then I personally place all importance on the last sentence on Page 2 of the Report.... "However, given the positive signs of efficacy to date and the potential of a positive readout, the prospects for attracting a big Pharma partner appear promising".
Blind Freddy can see such an outcome would generate multiples of 69 cents.
To me, even attempting to find a formula upon which to arrive at a valuation, is fraught with "under-valuation" risks.
- Forums
- ASX - By Stock
- VLA
- we value viralytics at a$0.69/share
we value viralytics at a$0.69/share, page-3
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries